Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268057 · ClinicalTrials.gov registry record · Phase 1
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Vaccinex.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT03268057 is a Phase 1 study that has completed, run by Vaccinex. The registered enrollment target is 62 participants.
The verdict
NCT03268057, a Phase 1 study, has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2503 administered in combination with avelumab.
Interventions
- DRUG VX15/2503 + avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2020-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03268057
The ClinicalTrials.gov registry entry for NCT03268057 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaccinex, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX15/2503 + avelumab is the first listed.
NCT03268057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03268057 about?
NCT03268057 is a clinical study titled "VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer". The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2...
What is the current status of trial NCT03268057?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-10-05. Estimated completion is 2020-09-10.
What interventions are being tested in trial NCT03268057?
The interventions under investigation include: VX15/2503 + avelumab (DRUG).
Who is sponsoring clinical trial NCT03268057?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.